

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Yu et al.

Docket No.: PF343P3C4

Patent No.: 6,881,401

Issued: April 19, 2005

For: Methods of Treatment of Immune System
Related Disorders Using Neutrokin-Alpha

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.322**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected. Applicants respectfully request publication of a Certificate of Corrections follows:

On the Title Page:

On page 1, under "Related U.S. Application Data," under INID code (63), line 2:
replace "and" with --which is--.

On page 1, under "Related U.S. Application Data," under INID code (63), line 5:
replace "and" with --which is--.

On page 2 under "Other Publications," under INID code (56), please insert the following three references which were cited by the Examiner:

Iglesias et al. 2001. Allergol Immunopathol. vol. 29, pages 113-118.
Common variable immunodeficiency. review.*

Saxon et al. 1993. Immunology. vol. 80, pages 477-487. Long-term administration of 13-cis retinoic acid in CVID.*

Basic and clinical Immunology, 1991. Ed. By Stites and Terr.
Chapter 24, pages 322-334.*

In the Claims:

Claim 53, at column 290:

Please replace "claim 53" with "claim 52".

Claim 68, at column 291:

Please replace "90or" with "90% or".

Support for the correction to the priority information on page 1 of the patent under INID code (63) can be found in the first paragraph of the application as filed on June 8, 2000.

Support for the missing references in the "Other Publications" section can be found in PTO Form 892 attached to the Office Action dated September 6, 2002 (see references U-W).

Support for the correction to claim 53 can be found in the presentation of claim 297 in Applicants amendment filed January 22, 2004. Claim 297 depended from claim 296 which were renumbered as claims 53 and 52, respectively.

Support for the correction to claim 68 can be found in the presentation of claim 314 in the Examiner's amendment that accompanied the Notice of Allowability mailed May 18, 2004.

The above mistakes were not in the application as filed or amended by Patentees, and thus appear to be the fault of the Patent and Trademark Office. Accordingly, it is hereby requested that a Certificate of Correction under 37 C.F.R. § 1.322 be issued for the above-identified patent. Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, no fee is required.

Submitted herewith is a proposed Certificate of Correction (Form PTO/SB/44). Patentees respectfully request the issuance of the Certificate of Correction.

Dated: July 28, 2006

Respectfully submitted,

By Michele Shannon
Michele Shannon
Registration No.: 47,075
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850
(301) 354-3930

KKH/MS/ba

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 6,881,401
APPLICATION NO. : 09/589,285
ISSUE DATE : April 19, 2005
INVENTOR(S) : Yu et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

On page 1, INID (63) - Related U.S. Application Data, line 2:
delete "and a" and insert --which is a--.

On page 1, INID (63) - Related U.S. Application Data, line 5:
delete "and a" and insert --which is a--.

On page 2, INID (56) - Other Publications, insert the following three references:

Iglesias et al. 2001. Allergol Immunopathol. vol. 29, pages 113-118. Common variable immunodeficiency. review.*

Saxon et al. 1993. Immunology. vol. 80, pages 477-487. Long-term administration of 13-cis retinoic acid in CVID.*

Basic and clinical Immunology, 1991. Ed. By Stites and Terr. Chapter 24, pages 322-334.*

In the Claims:

Claim 53, at column 290, delete "claim 53" and insert --claim 52--.

Claim 68, at column 291, delete "90or" and insert --90% or--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Michele Shannon
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850